Previous 10 | Next 10 |
home / stock / ivevf / ivevf articles
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company f...
LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with emp...
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...
Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-t...
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stag...
Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients wit...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inven...
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safet...
Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 3...
News, Short Squeeze, Breakout and More Instantly...
Daix, 21 June 2024 Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l’Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program a...
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dy...
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatit...